Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naïve rheumatoid arthritis patients is up-regulated and not influenced by 1 year of clinically effective treatment

Rheumatol Int. 2012 Feb;32(2):501-4. doi: 10.1007/s00296-010-1683-z. Epub 2011 Jan 19.

Abstract

The IGF-IR density on CD4+T-lymphocytes was studied using flow cytometry in 40 early steroid- and DMARD-naïve rheumatoid arthritis (RA) patients before and after 52 weeks of treatment with methotrexate+placebo or methotrexate+cyclosporine A and in 15 controls. RA patients had increased IGF-IR density on CD4+T-lymphocytes at week 0 and week 52, irrespective of treatment. IGF-IR-positive CD4+T-lymphocytes fraction decreased during treatment, but neither at week 0 nor at week 52 did it differ from healthy controls. No correlations were found to disease activity parameters.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / metabolism*
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / metabolism*
  • Drug Synergism
  • Drug Therapy, Combination / methods
  • Female
  • Humans
  • Insulin-Like Growth Factor I / metabolism*
  • Male
  • Middle Aged
  • Receptor, IGF Type 1 / biosynthesis
  • Receptor, IGF Type 1 / metabolism*
  • Steroids / administration & dosage
  • Steroids / therapeutic use*
  • Up-Regulation / drug effects*
  • Up-Regulation / immunology
  • Young Adult

Substances

  • Antirheumatic Agents
  • Steroids
  • Insulin-Like Growth Factor I
  • Receptor, IGF Type 1